Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 15/20 | 0.39 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL657295 | 0.77 | IRAK4 (0.37) | IRAK4AURKAMAP3K7FLT3SYK | |
| SCHEMBL30679394 | 0.77 | IRAK4 (0.37) | IRAK4AURKAMAP3K7FLT3SYK | |
| SCHEMBL21371622 | 0.77 | IRAK4 (0.37) | IRAK4IRAK1CYP17A1AURKAMAP3K7 | |
| SCHEMBL360516 | 0.75 | IRAK4 (0.39) | IRAK4CYP17A1AURKAMAP3K7FLT3 | |
| SCHEMBL29936180 | 0.75 | IRAK4 (0.39) | IRAK4CYP17A1AURKAMAP3K7FLT3 | |
| SCHEMBL29994731 | 0.73 | IRAK4 (0.33) | IRAK4IRAK1CYP17A1AURKAMAP3K7 | |
| SCHEMBL24375572 | 0.71 | IRAK4 (0.39) | IRAK4IRAK1AURKAMAP3K7FLT3 | |
| SCHEMBL22430212 | 0.71 | IRAK4 (0.36) | IRAK4IRAK1AURKAMAP3K7FLT3 | |
| SCHEMBL12162964 | 0.71 | IRAK4 (0.34) | IRAK4 | |
| SCHEMBL20594478 | 0.71 | IRAK4 (0.34) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2578590-B1 | ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KOREA INST SCI & TECH (KR) | 2017-08-16 | — | — | EP | disclosed |
| CN-102971327-B | There is the anti-inflammatory compound of multiple tyrosine-kinase enzyme inhibition activity and the pharmaceutical compositions containing these compounds | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-04-20 | — | — | CN | disclosed |
| US-9062066-B2 | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-06-23 | — | — | US | disclosed |
| EP-2578590-A2 | ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Korea Institute of Science and Technology (KR) | 2013-04-10 | — | — | EP | disclosed |
| US-20130072482-A1 | ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | PHAROSBIOMED CO., LTD. (KR) | 2013-03-21 | — | — | US | disclosed |
| CN-102971327-A | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same | KOREA INST SCI & TECH | 2013-03-13 | — | — | CN | disclosed |
| US-20090270391-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | KIRIN PHARMA KABUSHIKI KAISHA (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1870414-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING C-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | Kirin Pharma Kabushiki Kaisha (JP) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270391-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | MET, ABL1, RET | IRAK4 347/4885IRAK1 393/4885CYP17A1 4348/4885 |
| US-20130072482-A1 | ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | LCK, SRC, MAP3K1 | IRAK4 47/4885IRAK1 32/4885CYP17A1 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.